Log in to your Inderes Free account to see all free content on this page.
Enzymatica
1.46
SEK
-1.35 %
ENZY
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-1.35%
-9.32%
-7.59%
-18.89%
-16.9%
-54.89%
-68.41%
-72.77%
-74.44%
Enzymatica is a life science company that develops and sells medical devices for infection-related diseases. The products are based on barrier technology, which includes marine enzymes. The company's first product is ColdZyme® Mouth Spray which can prevent colds as well as shorten the illness period. The product has been launched on several markets and the strategy is to expand to more markets via partners. The company is headquartered in Lund.
Read moreMarket cap
354.39M SEK
Turnover
53.2K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
18.2.
2025
Annual report '24
29.4.
2025
Interim report Q1'25
17.7.
2025
Interim report Q2'25
ShowingAll content types
Enzymatica AB: Enzymatica focuses on growth with new recruitment - Anna Söderlund joins as Senior Director Marketing & Sales
Enzymatica AB: Interim report Q3/2024: Focus on developing existing and new markets
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio